Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2020-10-26 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
2020年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 Third Quarter Report" of Shenzhen Haiwang Bioengineering Co., Ltd. It contains detailed financial data including consolidated balance sheets, profit and loss statements, and other financial metrics for the third quarter ending September 30, 2020. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an interim or quarterly report. There is no indication that this is an announcement of a report or a certification document. The length and detail confirm it is the actual report itself, not just a publication announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2020
2020-10-26 Chinese
关于HW130注射液获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding the approval of a clinical trial for a drug (HW130 injection) by the National Medical Products Administration of China. It details the drug's development status, regulatory approval for clinical trials, and potential impact on the company. The document is short (1187 characters) and serves as an official notification of a regulatory milestone rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about clinical trial approval, which does not fit other specific categories like financial reports, management changes, or capital updates.
2020-10-21 Chinese
关于回购注销已不符合激励条件的激励对象已获授予但尚未解除限售的限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the repurchase and cancellation of restricted shares that no longer meet incentive conditions. It details the number of shares to be repurchased, the price, the source of funds, and the impact on share capital and shareholder structure. It also includes approvals from the board, supervisory committee, independent directors, and legal opinions. The document is a formal disclosure about a share repurchase and cancellation related to an employee stock incentive plan, not a financial report or earnings release. It does not contain financial statements or earnings data, nor is it a regulatory certification or a report publication announcement. The content fits the category of a Transaction in Own Shares (POS) because it concerns the company's repurchase and cancellation of its own shares under a stock incentive plan.
2020-10-09 Chinese
第八届董事局第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 13th meeting of the 8th Board of Directors of Shenzhen Haiwang Bioengineering Co., Ltd. It details the meeting date, attendance, voting results, and references other announcements for specific agenda items. The content focuses on board decisions and procedural compliance, without presenting financial data or detailed management discussion. The document length is short (862 characters), and it is clearly a board meeting resolution announcement rather than a full report or financial statement. Therefore, it fits best under Board/Management Information (MANG).
2020-10-09 Chinese
监事会关于第八届监事会第七次会议相关事项的意见
Transaction in Own Shares Classification · 95% confidence The document is a supervisory board opinion regarding the repurchase and cancellation of restricted shares granted to certain employees who no longer meet incentive conditions. It discusses internal company governance and stock incentive plan implementation details, specifically about share repurchase and cancellation under an existing stock incentive plan. It is not a full financial report, earnings release, or regulatory filing about financial results. It is also not a general announcement of a report publication but a detailed opinion on a specific corporate action related to share repurchase and cancellation. This fits best under Transaction in Own Shares (POS), which covers company buybacks or share cancellations.
2020-10-09 Chinese
关于回购注销已获授未解锁限制性股票的减资公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding the repurchase and cancellation of restricted shares that were granted but not yet unlocked. It details the reduction in registered capital due to this repurchase and informs creditors of their rights under Chinese company law. The document is short (733 characters) and focuses on a share repurchase and capital reduction event, not on financial results or management discussion. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or cancellations of its own shares.
2020-10-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.